JP2014530611A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530611A5 JP2014530611A5 JP2014535927A JP2014535927A JP2014530611A5 JP 2014530611 A5 JP2014530611 A5 JP 2014530611A5 JP 2014535927 A JP2014535927 A JP 2014535927A JP 2014535927 A JP2014535927 A JP 2014535927A JP 2014530611 A5 JP2014530611 A5 JP 2014530611A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- bms2h
- gly
- antibody polypeptide
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 51
- 102000004196 processed proteins & peptides Human genes 0.000 claims 51
- 108090000765 processed proteins & peptides Proteins 0.000 claims 51
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 208000026278 immune system disease Diseases 0.000 claims 10
- 230000004927 fusion Effects 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 206010052779 Transplant rejections Diseases 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 101100059511 Homo sapiens CD40LG gene Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 108010029697 CD40 Ligand Proteins 0.000 claims 2
- 102100032937 CD40 ligand Human genes 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 2
- 102000007562 Serum Albumin Human genes 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- FLNPJLDPGMLWAU-UWVGGRQHSA-N Leu-Met-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(C)C FLNPJLDPGMLWAU-UWVGGRQHSA-N 0.000 claims 1
- 208000007466 Male Infertility Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034038 Parotitis Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- HEQPKICPPDOSIN-SRVKXCTJSA-N Ser-Asp-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HEQPKICPPDOSIN-SRVKXCTJSA-N 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 210000000918 epididymis Anatomy 0.000 claims 1
- 201000010063 epididymitis Diseases 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161546800P | 2011-10-13 | 2011-10-13 | |
| US61/546,800 | 2011-10-13 | ||
| US201261655110P | 2012-06-04 | 2012-06-04 | |
| US61/655,110 | 2012-06-04 | ||
| PCT/US2012/059977 WO2013056068A1 (en) | 2011-10-13 | 2012-10-12 | Antibody polypeptides that antagonize cd40l |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530611A JP2014530611A (ja) | 2014-11-20 |
| JP2014530611A5 true JP2014530611A5 (enExample) | 2015-10-29 |
| JP6163158B2 JP6163158B2 (ja) | 2017-07-12 |
Family
ID=47046896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535927A Active JP6163158B2 (ja) | 2011-10-13 | 2012-10-12 | Ｃｄ４０ｌに拮抗する抗体ポリペプチド |
Country Status (31)
| Country | Link |
|---|---|
| US (7) | US8895010B2 (enExample) |
| EP (1) | EP2766395B1 (enExample) |
| JP (1) | JP6163158B2 (enExample) |
| KR (1) | KR101637915B1 (enExample) |
| CN (1) | CN104245732B (enExample) |
| AR (1) | AR088455A1 (enExample) |
| AU (2) | AU2012322093C1 (enExample) |
| BR (1) | BR112014009069A2 (enExample) |
| CA (1) | CA2851814C (enExample) |
| CL (1) | CL2014000958A1 (enExample) |
| CO (1) | CO7020864A2 (enExample) |
| CY (1) | CY1123618T1 (enExample) |
| DK (1) | DK2766395T3 (enExample) |
| EA (1) | EA030852B1 (enExample) |
| ES (1) | ES2769806T3 (enExample) |
| HR (1) | HRP20200230T1 (enExample) |
| HU (1) | HUE048365T2 (enExample) |
| IL (1) | IL231925B (enExample) |
| LT (1) | LT2766395T (enExample) |
| MX (1) | MX357231B (enExample) |
| PE (1) | PE20141478A1 (enExample) |
| PL (1) | PL2766395T3 (enExample) |
| PT (1) | PT2766395T (enExample) |
| RS (1) | RS60021B1 (enExample) |
| SG (2) | SG10201610288TA (enExample) |
| SI (1) | SI2766395T1 (enExample) |
| SM (1) | SMT202000091T1 (enExample) |
| TW (1) | TWI585102B (enExample) |
| UY (1) | UY34394A (enExample) |
| WO (1) | WO2013056068A1 (enExample) |
| ZA (1) | ZA201402603B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202000091T1 (it) | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| US20140106405A1 (en) * | 2012-10-15 | 2014-04-17 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| KR20160124912A (ko) * | 2014-03-19 | 2016-10-28 | 브리스톨-마이어스 스큅 컴퍼니 | Cd40l에 대해 지시된 도메인 항체를 사용하여 이식 거부를 치료하는 방법 |
| CN104090115B (zh) * | 2014-07-10 | 2016-01-13 | 上海益诺思生物技术有限公司 | 次级t细胞依赖抗体反应检测外源性化合物免疫抑制方法 |
| EA201790520A1 (ru) * | 2014-09-10 | 2017-07-31 | Бристол-Маерс Сквибб Компани | Способы лечения аутоиммунного заболевания с применением доменного антитела, специфического к cd40l |
| KR101760707B1 (ko) * | 2015-01-05 | 2017-07-24 | 한림대학교 산학협력단 | 이종 알부민을 이용한 장기 이식 거부반응 검사용 키트 |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| US9512229B2 (en) * | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| KR101752280B1 (ko) | 2015-03-31 | 2017-06-30 | 서울대학교산학협력단 | 영장류 cd154에 특이적인 항체 및 이를 생산하는 융합 세포주 |
| HUE051896T2 (hu) | 2015-07-16 | 2021-03-29 | Inhibrx Inc | Multivalens és multispecifikus DR5-kötõ fúziós fehérjék |
| CA2994825A1 (en) | 2015-08-05 | 2017-02-09 | Janssen Biotech, Inc. | Anti-cd154 antibodies and methods of using them |
| MX2018003905A (es) | 2015-09-30 | 2018-09-06 | Janssen Biotech Inc | Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso. |
| JP2018536404A (ja) | 2015-11-09 | 2018-12-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法 |
| CN105353135A (zh) * | 2015-11-23 | 2016-02-24 | 中国人民解放军第三军医大学第一附属医院 | 阿尔茨海默病标志物的用途 |
| CA3006398A1 (en) * | 2015-11-27 | 2017-06-01 | Ablynx Nv | Polypeptides inhibiting cd40l |
| US20190086405A1 (en) | 2016-03-16 | 2019-03-21 | Bristol-Myers Squibb Company | Methods of diagnosing and treating lupus |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| CA3029003A1 (en) | 2016-06-27 | 2018-01-04 | The Regents Of The University Of California | Cancer treatment combinations |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| CN106967171B (zh) * | 2017-02-23 | 2021-04-27 | 郑州大学 | 一种全人源重组CD40L单抗Fab片段及其制备方法 |
| US11440951B2 (en) | 2017-03-13 | 2022-09-13 | The Government Of The United States, As Represented By The Secretary Of The Army | Therapeutic antibodies to Marburg virus |
| EP3630843A2 (en) | 2017-05-24 | 2020-04-08 | ALS Therapy Development Institute | Therapeutic anti-cd40 ligand antibodies |
| BR112021023048A2 (pt) | 2019-05-21 | 2022-04-19 | Novartis Ag | Moléculas de ligação a cd19 e usos das mesmas |
| SMT202400527T1 (it) * | 2019-07-01 | 2025-01-14 | Tonix Pharma Ltd | Anticorpi anti-cd154 e loro usi |
| KR20210006301A (ko) * | 2019-07-08 | 2021-01-18 | 주식회사 프로젠 | 신규 융합단백질 및 그의 용도 |
| US20210032356A1 (en) * | 2019-08-02 | 2021-02-04 | Eastern Virginia Medical School | Method for treating seizures |
| WO2021113648A1 (en) * | 2019-12-06 | 2021-06-10 | The University Of North Carolina At Chapel Hill | Affinity molecules that direct the metabolism and polarization of macrophages and synergize the immune checkpoint blockade therapy |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| CA3207098A1 (en) | 2021-01-06 | 2022-07-14 | Tonix Pharma Limited | Methods of inducing immune tolerance with modified anti-cd154 antibodies |
| CN114149508B (zh) * | 2021-11-25 | 2023-04-28 | 苏州普乐康医药科技有限公司 | 一种结合cd40l的融合蛋白及其应用 |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
| WO2024249042A2 (en) * | 2023-05-26 | 2024-12-05 | Vanderbilt University | Human monoclonal antibodies for human parainfluenza virus type 3 |
| WO2025248134A1 (en) | 2024-05-31 | 2025-12-04 | Tonix Pharma Limited | Treatment methods comprising administration of modified cd154 antibodies |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| CN1835976B (zh) * | 2003-06-13 | 2012-06-13 | 比奥根艾迪克Ma公司 | 无糖基抗-cd154(cd40配体)抗体及其用途 |
| JP4667383B2 (ja) * | 2003-06-13 | 2011-04-13 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用 |
| DK1639011T3 (da) | 2003-06-30 | 2009-02-16 | Domantis Ltd | Pegylerede enkelt-domæne antistoffer (dAb) |
| CN101443043A (zh) * | 2003-10-08 | 2009-05-27 | 杜门蒂斯有限公司 | 抗体组合物和方法 |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| CN101061140B (zh) * | 2004-09-17 | 2015-07-01 | 多曼蒂斯有限公司 | 单价结合cd40l的组合物和应用方法 |
| LT1868635T (lt) | 2005-04-06 | 2017-07-10 | Bristol-Myers Squibb Company | Imuninių sutrikimų, susijusių su transplantato persodinimu, gydymo būdas tirpiomis mutantinėmis ctla4 molekulėmis |
| CA2634547C (en) | 2005-12-20 | 2016-10-11 | Bristol-Myers Squibb Company | Stable ctla4 formulation for subcutaneous administration |
| EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| PL2125894T3 (pl) * | 2007-03-22 | 2019-08-30 | Biogen Ma Inc. | Białka wiążące, w tym przeciwciała, pochodne przeciwciał i fragmenty przeciwciał, które swoiście wiążą się z CD154 i ich zastosowania |
| GB0815788D0 (en) * | 2008-08-29 | 2008-10-08 | Isis Innovation | Therapeutic antibodies |
| RS60612B1 (sr) | 2010-03-31 | 2020-08-31 | Boehringer Ingelheim Int | Anti-cd40 antitela |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| EP3604330A1 (en) | 2011-02-25 | 2020-02-05 | Chugai Seiyaku Kabushiki Kaisha | Fcgammariib-specific fc antibody |
| US9475879B2 (en) | 2011-04-21 | 2016-10-25 | Bristol-Myers Squibb Company | Antibody polypeptides that antagonize CD40 |
| SMT202000091T1 (it) * | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| SG11201404751UA (en) | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| KR20160124912A (ko) | 2014-03-19 | 2016-10-28 | 브리스톨-마이어스 스큅 컴퍼니 | Cd40l에 대해 지시된 도메인 항체를 사용하여 이식 거부를 치료하는 방법 |
-
2012
- 2012-10-11 SM SM20200091T patent/SMT202000091T1/it unknown
- 2012-10-12 AR ARP120103816A patent/AR088455A1/es unknown
- 2012-10-12 JP JP2014535927A patent/JP6163158B2/ja active Active
- 2012-10-12 ES ES12775423T patent/ES2769806T3/es active Active
- 2012-10-12 SI SI201231719T patent/SI2766395T1/sl unknown
- 2012-10-12 TW TW101137824A patent/TWI585102B/zh not_active IP Right Cessation
- 2012-10-12 DK DK12775423.2T patent/DK2766395T3/da active
- 2012-10-12 UY UY0001034394A patent/UY34394A/es unknown
- 2012-10-12 SG SG10201610288TA patent/SG10201610288TA/en unknown
- 2012-10-12 LT LTEP12775423.2T patent/LT2766395T/lt unknown
- 2012-10-12 PL PL12775423T patent/PL2766395T3/pl unknown
- 2012-10-12 PE PE2014000522A patent/PE20141478A1/es active IP Right Grant
- 2012-10-12 EP EP12775423.2A patent/EP2766395B1/en active Active
- 2012-10-12 US US13/650,493 patent/US8895010B2/en active Active
- 2012-10-12 AU AU2012322093A patent/AU2012322093C1/en not_active Ceased
- 2012-10-12 CA CA2851814A patent/CA2851814C/en not_active Expired - Fee Related
- 2012-10-12 SG SG11201401385YA patent/SG11201401385YA/en unknown
- 2012-10-12 WO PCT/US2012/059977 patent/WO2013056068A1/en not_active Ceased
- 2012-10-12 RS RS20200157A patent/RS60021B1/sr unknown
- 2012-10-12 CN CN201280061977.3A patent/CN104245732B/zh not_active Expired - Fee Related
- 2012-10-12 KR KR1020147012398A patent/KR101637915B1/ko active Active
- 2012-10-12 PT PT127754232T patent/PT2766395T/pt unknown
- 2012-10-12 HU HUE12775423A patent/HUE048365T2/hu unknown
- 2012-10-12 EA EA201490745A patent/EA030852B1/ru not_active IP Right Cessation
- 2012-10-12 MX MX2014004293A patent/MX357231B/es active IP Right Grant
- 2012-10-12 BR BR112014009069-6A patent/BR112014009069A2/pt not_active Application Discontinuation
- 2012-10-12 HR HRP20200230TT patent/HRP20200230T1/hr unknown
-
2013
- 2013-12-10 US US14/101,441 patent/US8981072B2/en active Active
-
2014
- 2014-04-03 IL IL23192514A patent/IL231925B/en active IP Right Grant
- 2014-04-09 ZA ZA2014/02603A patent/ZA201402603B/en unknown
- 2014-04-10 CO CO14078322A patent/CO7020864A2/es unknown
- 2014-04-14 CL CL2014000958A patent/CL2014000958A1/es unknown
- 2014-10-09 US US14/510,474 patent/US9228018B2/en active Active
-
2015
- 2015-11-24 US US14/950,949 patent/US9765150B2/en active Active
-
2016
- 2016-04-28 AU AU2016202717A patent/AU2016202717A1/en not_active Abandoned
-
2017
- 2017-08-03 US US15/668,305 patent/US10196451B2/en active Active
-
2018
- 2018-12-12 US US16/218,077 patent/US11180567B2/en active Active
-
2020
- 2020-02-18 CY CY20201100147T patent/CY1123618T1/el unknown
-
2021
- 2021-11-09 US US17/522,008 patent/US20220073636A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530611A5 (enExample) | ||
| JP2014513953A5 (enExample) | ||
| JP2017099391A5 (enExample) | ||
| HRP20200230T1 (hr) | Polipeptidi antitijela koji antagoniziraju cd40l | |
| JP6548696B2 (ja) | ヒト抗ｉｌ−３３中和モノクローナル抗体 | |
| AU2015232352B2 (en) | Antibody-fynomer conjugates | |
| JP2020521458A5 (enExample) | ||
| CN106573053B (zh) | 干扰素α和ω抗体拮抗剂 | |
| CN108473563B (zh) | 改进的tnf结合剂 | |
| JP2020124205A (ja) | Ｉｌ−２３ａ及びｔｎｆ−アルファを標的とする化合物ならびにその使用 | |
| JP2010500005A5 (enExample) | ||
| JP2014511844A5 (enExample) | ||
| WO2017215524A1 (zh) | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 | |
| TWI797124B (zh) | 抗干擾素-γ之抗體及其應用 | |
| JP2014503209A5 (enExample) | ||
| IL291571B2 (en) | Cx3cr1-binding polypeptides | |
| RU2011135422A (ru) | Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний | |
| JP2008508864A5 (enExample) | ||
| TW200831533A (en) | Interleukin-13 binding proteins | |
| JP2011506422A5 (enExample) | ||
| RU2007142444A (ru) | Улучшенные нанотела против фактора некроза опухоли-альфа | |
| JP7189211B2 (ja) | 血清中のタンパク質の半減期を増加させるための組成物及び方法 | |
| WO2015137843A1 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| TW201233795A (en) | Chemokine receptor binding polypeptides | |
| KR101646830B1 (ko) | Ｂ형 간염 바이러스를 중화시킬 수 있는 결합 분자 |